



IACM 2020

FREE
ONLINE EVENTS

WEBINAR SERIES
&
ANNIVERSARY
ONLINE MEETING

HELD ONLINE IN
OCT - NOV 2020

IN CLOSE COLLABORATION
WITH ASOCIACIÓN
MEXICANA DE MEDICINA
CANNABINOIDE A.C.
(AMMCANN)



INVITATION FOR PARTICIPATION



ASOCIACIÓN
MEXICANA DE MEDICINA
CANNABINOIDE A.C.

cannabinoid
medicines International
Association for Cannabinoid Medicines

Reasons to attend

0€

The entire webinar series and the special anniversary online meeting are **both free** to watch and attend while requiring only a **single registration** for all free online events.

#1

These are the **first free** online events by the IACM. It is a unique chance to learn from the **best of the best** in science and attend IACM's **20th anniversary** celebration.



All webinars will be held in **English**. And for the first time, **subtitles** are available in **German, French, Spanish, and Portuguese**.



The webinar series will be available for up to **6 months** as **on demand recordings** from October 2020 until March 2021.



Participants can **interact** with sponsors that showcase their area of expertise from around the world.

Schedule

The entire webinar series and the special anniversary online meeting are **both free** to watch and attend while requiring only a **single registration** with our host (Congrex).

Visit the following web page on our web site for the **latest information** and **to register**:
<http://www.cannabis-med.org/index.php?tpl=page&id=318&lng=en>

All webinars will be held in **English with subtitles** in German, French, Spanish, and Portuguese. Only the webinar series will available online afterwards as **on demand recordings** from October 2020 **until March 2021** on the web site of our host (Congrex).

The anniversary online meeting to celebrate the IACM's **20th anniversary** and to honour the **90th birthday** of Raphael Mechoulam, who was born on **5th November 1930**, will be a **live session** that will not be available afterwards on the web site of our host (Congrex).

All webinars (on demand) and the anniversary online meeting (live)

No	Type	Name	Title	Release
1	Presentation (webinar)	Ethan Russo	Plants and the endocannabinoid system	08. October 2020 6pm CEST *
2	Presentation (webinar)	Roger Pertwee	Potential therapeutic uses of certain cannabis-derived and synthetic cannabinoids revealed by their pharmacological properties	15. October 2020 6pm CEST *
3	Debate (webinar)	Donald Abrams & Manuel Guzmán	Cannabis in cancer	22. October 2020 6pm CEST *
4	Presentation (webinar)	Raphael Mechoulam	A look back and ahead	29. October 2020 6pm CET *
5	Meeting (live session)		Special anniversary online meeting to celebrate the IACM's 20th anniversary and to honour the 90th birthday of Raphael Mechoulam	05. November 2020 (time to be announced) *
6	Presentation (webinar)	Daniele Piomelli	Overview of the endocannabinoid system	12. November 2020 6pm CET *
7	Presentation (webinar)	Kirsten Müller-Vahl	Cannabinoids in psychiatric disorders	19. November 2020 6pm CET *
8	Debate (webinar)	Franjo Grotenhermen & Bonni Goldstein	How to start a treatment with cannabis and cannabinoids	26. November 2020 6pm CET *

* **CEST** is Central European **Summer Time** (UTC+2) but **CET** is Central European Time (UTC+1) during **winter time**.

* You can use the following time conversion web page to convert the stated time directly to the time in your location:

https://www.timeanddate.com/worldclock/converter.html?iso=20201105T170000&p1=tz_cet

Sponsors of our free online events

We would like to thank our sponsors for their generous sponsorship of all of our free online events this year!

We invite all participants to get to know our sponsors and learn more about their products at their interactive virtual booths during the webinar series by clicking on one of their logos seen below, which will open the virtual booth of the corresponding sponsor in a web browser (the names and logos of all of our sponsors will follow soon).

Speakers (1/3)



Dr. Donald I. Abrams, M.D. is an oncologist and Professor of Clinical Medicine at the University of California San Francisco. He has been studying the health effects of botanical cannabis since 1997. He was a member of the National Academies of Sciences, Engineering and Medicine's committee that produced *The Health Effects of Cannabis and Cannabinoids*, published in 2017.

Dr. Abrams was a member of the International Association of Cannabinoid Medicine's Executive Board for many years and he was the 2007 recipient of the IACM Award for Clinical Research.



Dr. Bonni Goldstein, M.D. is the Medical Director of Canna-Centers Wellness and Education, a Los Angeles-based medical practice devoted to helping patients use cannabis for serious and chronic medical conditions. After years of working in the specialty of Pediatric Emergency medicine, she developed an interest in the science of medical cannabis after witnessing its beneficial effects in an ill friend.

Since then Dr. Goldstein has evaluated thousands of patients for its use, with a focus on treating children with intractable epilepsy, autism, and cancer. Her book *Cannabis is Medicine 2* will be published in September 2020.



Dr. Franjo Grotenhermen, M.D. is Executive Director of the German Arbeitsgemeinschaft Cannabis als Medizin e.V. (ACM), Executive Director of the International Association for Cannabinoid Medicines e.V. (IACM), co-owner of Endoxo GmbH (founded in 2019) and Head of Scientific Committee of MYCB1 GmbH (since 2019).


Furthermore, he is Honorary President of the Union Francophone pour les Cannabinoïdes en Médecine (UFCM) and member of the Scientific Advisory Board of Portugal Medical Cannabis (PTMC). He has received the following awards: Hemp Prize 1999 of Cannabusiness, IACM 2011 Special Award, ICBC 2018 Lifetime Achievement Award, Robert Newman Memorial Prize 2018 of Akzept e.V.

Speakers (2/3)



Dr. Manuel Guzmán is a Professor of Biochemistry and Molecular Biology at Madrid Complutense University. His research work has allowed to characterize new effects and signaling pathways evoked by cannabinoid receptors, as well as putting forward new physiopathological implications derived from them.

Dr. Guzmán has published 150 scientific articles and has 7 patents, and he has supervised 20 PhD theses. He is an Academic Member of The Spanish Royal Academy of Pharmacy, as well as a member of the Board of Directors of the IACM.



Dr. Raphael Mechoulam studied biochemistry at the Hebrew University and the Weizmann Institute. He acted as senior lecturer, associate and full professor and also as rector of the Hebrew University. In 2000 he retired but continued his research on the chemistry of natural products.

Mechoulam published about 450 scientific papers and received numerous national and international prizes. Furthermore, he was granted honorary PhDs from several universities in America and Europe.



Dr. Kirsten Müller-Vahl, M.D. is a Professor of Psychiatry at the Hannover Medical School (MHH). She is the head of the Tourette syndrome outpatient department at the MHH, the 1. Chairwoman of the ACM and a founding member as well as the first Chairwoman of the IACM.

Since 2016, Dr. Müller-Vahl has been member of the committee of experts for narcotic drugs at the federal opium bureau of the Federal Institute for Drugs and Medical Devices (BfArM) in Germany. In 2017 she received the IACM Award for Clinical Research for her special achievements regarding the re-introduction of cannabis and cannabinoids as medicine.

Speakers (3/3)



Dr. Dr. Roger Pertwee, MA D.Phil. D.Sc. (Oxford) is an Emeritus Professor at the University of Aberdeen, an Honorary Fellow of the British Pharmacological Society (BPS) and has served as President of the International Cannabinoid Research Society (ICRS) as well as as Chairman of the IACM.

Dr. Pertwee was awarded the 2002 Mechoulam Award and the 2018 Lifetime Achievement Award from the ICRS, the 2011 Wellcome Gold Medal for outstanding contributions to pharmacology, and the 2013 IACM Special Award and a 2018 and 2019 Highly Cited Researcher Award from Clarivate Analytics in recognition of the production of Pharmacology papers ranking in the top 1% by citations.



Dr. Daniele Piomelli studied pharmacology and neuroscience at Columbia and at Rockefeller University. Now he works at the University of California where he acts as Louise Turner Arnold Chair in Neurosciences and Distinguished Professor of Anatomy and Neurobiology, Pharmaceutical Sciences and Biological Chemistry. Daniele has written more than 400 peer-reviewed articles, three full-length books, and has 34 patents.

He founded the department of drug discovery and development at the Italian Institute of Technology and three biopharmaceutical start-ups. Furthermore, he codirects the UCI's Center for the Study of Cannabis and is Editor-in-Chief of the peer-reviewed journal, Cannabis and Cannabinoid Research.



Dr. Ethan Russo, M.D. is a board-certified neurologist, psychopharmacology researcher, and Founder/CEO of CReDO Science. Previously he was Director of Research and Development for the International Cannabis and Cannabinoids Institute (2017 - 2019), Medical Director of PHYTECS (2015 - 2017), and Senior Medical Advisor and medical monitor/study physician to GW Pharmaceuticals (2003 - 2014) for numerous Phase I-III clinical trials of Sativex® and Epidiolex®.

Dr. Russo is author/editor of seven books and has published more than 50 peer-reviewed articles.

Profile of the IACM



Two decades of the IACM - 20 years of supporting research and activities towards the medicinal use of cannabis and cannabinoids

The German *Association for Cannabis as Medicine e.V.* (ACM) - a handful of enthusiastic medical doctors from Germany, Switzerland, and Austria - supported by experts from other countries founded the *International Association for Cannabinoid Medicines e.V.* (IACM) in March 2000.

During the past 20 years, the IACM evolved towards the most important scientific association for clinical research in the field of cannabis-based medicines.

The overarching aim of the IACM is to advance the knowledge on cannabis, cannabinoids, the endocannabinoid system and related topics - especially with regard to their therapeutic potential, which would allow more patients to profit from a treatment with cannabis-based medicines and ease legislators to adopt their policies.

In order to reach this goal, the IACM organizes international scientific conferences; it publishes a biweekly newsletter that is currently available in six different languages and reaches more than 5000 people worldwide; and it is working closely together with patient associations, international partner organizations and IACM ambassadors. Since 2019, the journal *Cannabis and Cannabinoid Research* is the official journal of the IACM. There is also a partnership with the journal *Medical Cannabis and Cannabinoids*.



Contacts for participants

International Association for Cannabinoid Medicines e.V. (IACM)

Bahnhofsallee 9
32839 Steinheim
Germany

T: +49 5233 953 9213
F: +49 5233 953 7095
E: info@cannabis-med.org

Asociación Mexicana de Medicina Cannabinoide A.C. (AMMCann)

Roberto Gayol 34
Col del Valle Centro
Benito Juárez
03100 Ciudad de México, CDMX
Mexico

T: +52 55 7159 9726
E: info@ammcann.org